CY1117505T1 - SUPPLEMENTARY BATTERY ADMINISTRATION AND FACTORS AGAINST CY C5 USEFUL IN EDUCATION AGAINST EYE DISEASES - Google Patents

SUPPLEMENTARY BATTERY ADMINISTRATION AND FACTORS AGAINST CY C5 USEFUL IN EDUCATION AGAINST EYE DISEASES

Info

Publication number
CY1117505T1
CY1117505T1 CY20161100203T CY161100203T CY1117505T1 CY 1117505 T1 CY1117505 T1 CY 1117505T1 CY 20161100203 T CY20161100203 T CY 20161100203T CY 161100203 T CY161100203 T CY 161100203T CY 1117505 T1 CY1117505 T1 CY 1117505T1
Authority
CY
Cyprus
Prior art keywords
useful
education
eye diseases
factors
supplementary battery
Prior art date
Application number
CY20161100203T
Other languages
Greek (el)
Inventor
David Epstein
Jeffrey C Kurz
Original Assignee
Archemix Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP12173138.4A external-priority patent/EP2596807B1/en
Application filed by Archemix Llc filed Critical Archemix Llc
Publication of CY1117505T1 publication Critical patent/CY1117505T1/en

Links

Abstract

Μέθοδοι αγωγής έναντι οφθαλμικών διαταραχών που διαμεσολαβούνται από το συμπλήρωμα και που ενέχουν χορήγηση παραγόντων οι οποίοι αναστέλλουν ένα συστατικό του συμπληρώματος ενός ατόμου υπό ποσό επαρκές προς αγωγή έναντι της οφθαλμικής διαταραχής όπου, σε μία επιλεγμένη υλοποίηση, ο αναφερθείς παράγοντας είναι ένα απταμερές έναντι του συμπληρώματος το οποίο, σε μία προτιμούμενη υλοποίηση, είναι ένα απταμερές έναντι του C5.Methods of treatment for complement-mediated ocular disorders involving administration of agents which inhibit a component of a person's complement in an amount sufficient to treat ocular disorder where, in a selected embodiment, the agent is which, in a preferred embodiment, is an apatomere with respect to C5.

CY20161100203T 2006-03-08 2016-03-08 SUPPLEMENTARY BATTERY ADMINISTRATION AND FACTORS AGAINST CY C5 USEFUL IN EDUCATION AGAINST EYE DISEASES CY1117505T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78090506A 2006-03-08 2006-03-08
US84827406A 2006-09-29 2006-09-29
EP12173138.4A EP2596807B1 (en) 2006-03-08 2007-03-08 Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders

Publications (1)

Publication Number Publication Date
CY1117505T1 true CY1117505T1 (en) 2017-04-26

Family

ID=58457110

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20151100047T CY1115965T1 (en) 2006-03-08 2015-01-16 SUPPLEMENTARY BATTERY ADMINISTRATION AND FACTORS AGAINST CY C5 USEFUL IN EDUCATION AGAINST EYE DISEASES
CY20161100203T CY1117505T1 (en) 2006-03-08 2016-03-08 SUPPLEMENTARY BATTERY ADMINISTRATION AND FACTORS AGAINST CY C5 USEFUL IN EDUCATION AGAINST EYE DISEASES

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20151100047T CY1115965T1 (en) 2006-03-08 2015-01-16 SUPPLEMENTARY BATTERY ADMINISTRATION AND FACTORS AGAINST CY C5 USEFUL IN EDUCATION AGAINST EYE DISEASES

Country Status (1)

Country Link
CY (2) CY1115965T1 (en)

Also Published As

Publication number Publication date
CY1115965T1 (en) 2017-01-25

Similar Documents

Publication Publication Date Title
MX2008006076A (en) Methods, compositions, and kits for the treatment of medical conditions.
CY1121408T1 (en) PREVENTION AND TREATMENT OF CONCLUSION DISEASE AND STYLE DISEASE
CY1115617T1 (en) USE OF PATIENTS IN TREATMENT OF DISEASES THAT ARE CONCERNED WITH THE PROTEIN TOWARDS WHICH INCLUDE THE DISEASE
DE602004028920D1 (en) BY
EA200901211A1 (en) ANTIGENS OF C5 PROTEIN AND THEIR APPLICATION
SG146653A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
UY29284A1 (en) AB (BETA) HUMANIZED ANTIBODIES USED TO IMPROVE COGNITION
CR8095A (en) HUMANIZED ANTIBODIES RECOGNIZING THE BETA AMILOIDEO BODY
WO2007103549A3 (en) Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
NO20076241L (en) Vascular disease therapies
EA200700427A1 (en) PREVENTION AND TREATMENT OF SYNUCLEOPATHIC AND AMYLOIDOGENIC DISEASES
EA200400518A1 (en) METHODS OF TREATING EYE NONASCULAR DISEASES
DK1814590T3 (en) Treatment of obesity and related diseases
ATE502633T1 (en) CYCLOSPORINS FOR THE TREATMENT AND PREVENTION OF EYE DISEASES
SG147442A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
MX2007010752A (en) Ophthalmic uses of s1p receptor modulators.
CY1110182T1 (en) IDEENONON FOR THE TREATMENT OF MUSCLE DYSTROPHY
DE602004023183D1 (en) PHOTODYNAMIC THERAPY PROVIDED AGAINST ANTIBODIES
CR9200A (en) USE OF A 5-HT6 AGONIST FOR THE TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISORDERS
MX2020009532A (en) Modified oligonucleotides for use in treatment of tauopathies.
GB0606015D0 (en) therapeutic agents
WO2006012521A3 (en) Treatment for ocular disease
WO2008042314A3 (en) Diagnosis and treatment of disorders of the eye
CY1117505T1 (en) SUPPLEMENTARY BATTERY ADMINISTRATION AND FACTORS AGAINST CY C5 USEFUL IN EDUCATION AGAINST EYE DISEASES
EP1297849A4 (en) Remedial agent for optic nerve disease and the like